content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED ADVISORS LLC -->
            <cik>0001055951</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001699382</issuerCik>
        <issuerName>PMV Pharmaceuticals, Inc.</issuerName>
        <secFileNumber>001-39539</secFileNumber>
        <issuerAddress>
          <com:street1>One Research Way</com:street1>
          <com:city>Princeton</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>08540</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>609-642-6670</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Genesis Master Fund, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Shareholder</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Themis Trading LLC</name>
          <address>
            <com:street1>10 Townsquare</com:street1>
            <com:city>Chatham</com:city>
            <com:stateOrCountry>NJ</com:stateOrCountry>
            <com:zipCode>07928</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>87786</noOfUnitsSold>
        <aggregateMarketValue>197519.00</aggregateMarketValue>
        <noOfUnitsOutstanding>51157636</noOfUnitsOutstanding>
        <approxSaleDate>11/22/2023</approxSaleDate>
        <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <acquiredDate>09/29/2020</acquiredDate>
        <natureOfAcquisitionTransaction>Initial Public Offering</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>87786</amountOfSecuritiesAcquired>
        <paymentDate>09/29/2020</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <remarks>OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC.</remarks>
      <noticeSignature>
        <noticeDate>11/22/2023</noticeDate>
        <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Genesis Master Fund, L.P.</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 3121}]
text: 144
  0001055951
  XXXXXXXX
  LIVE
  0001699382
  PMV Pharmaceuticals, Inc.
  001-39539
  One Research Way
  Princeton
  NJ
  08540
  609-642-6670
  OrbiMed Genesis Master Fund, L.P.
  Shareholder
  Common Stock
  Themis Trading LLC
  10 Townsquare
  Chatham
  NJ
  07928
  87786
  197519.00
  51157636
  11/22/2023
  Nasdaq Stock Market
  Common Stock
  09/29/2020
  Initial Public Offering
  Issuer
  N
  87786
  09/29/2020
  Cash
  Y
  OrbiMed Genesis GP LLC is the general partner of OrbiMed Genesis Master Fund, L.P. OrbiMed Advisors LLC is the managing member of OrbiMed Genesis GP LLC.
  11/22/2023
  /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Genesis Master Fund, L.P.